An innovative study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved unprecedented pathologic responses, with no recurrences.
The addition of pembrolizumab (Keytruda) to trastuzumab (Herceptin) and platinum-based chemotherapy led to a significant improvement in overall response rate.